ClinicalTrials.gg
CompletedNCT01559545Updated Jun 7, 2013

A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis

A Phase 2 interventional study of Metronidazole and Metronidazole-DRF1 in Clostridium Difficile Associated Diarrhea, sponsored by Dr. Reddy's Laboratories Limited. Completed at 12 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-07.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Diarrhea with a site in India — none open to participants now, 1 under way, none of them phase 3. Diarrhea · India.

Enrollment
39th of 40
60 · median 918
Started
2012
the only one that year
Phase 2
7 of 42
none open now
Registered
26th of 42
by date

Among the 42 studies in Diarrhea with a site in India, this one is the 39th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 2, and was the 26th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

None of the 42 studies in Diarrhea with a site in India is open now. The open studies under Diarrhea, anywhere →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies in Diarrhea with a site in India as a file.
02

Study summary

Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic.

This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon.

03

Conditions studied

  • Clostridium Difficile Associated Diarrhea

Browse trials for

Keywords

  • Clostridium difficile associated diarrhea
  • Metronidazole
  • CDAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients 18 years of age or older
  2. Mild to moderate C.difficile associated diarrhea (CDAD) with a positive stool C.difficile toxin (by ELISA).
  3. Either a first episode of CDAD or a first recurrence (patients with more than 1 recurrence are not eligible)
  4. Greater than 3 watery or unformed bowel movements in the prior 24 hours
  5. Females of child bearing potential having a negative pregnancy test and taking adequate measures.
  6. Patients should not consume alcohol at least 12 hours prior to dosing (i.e. in-house monitoring) and until 48 hours after the last dose of drug administration (until Day 14).
  7. Able to comprehend and give for the study and able to adhere to study schedules and protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known prior history of to metronidazole or other nitroimidazole derivatives
  2. ≤ 60 days
  3. Sepsis, severe sepsis, or septic shock
  4. Signs or symptoms of peritonitis, megacolon or ileus
  5. History of ulcerative colitis or Crohn's disease
  6. Oral or parenteral antibiotic therapy with metronidazole or vancomycin or other drugs effective in treating DCAD (e.g., bacitracin, fusidic acid) within the 1 week prior to enrollment
  7. Recent history of significant drug or alcohol abuse within 1 year
  8. Any findings on physical examination, medical history, 12-lead or clinical laboratory tests which, in the judgment of the Principal Investigator, would exclude patients from participating in the study
  9. Patients with history of blood dyscrasias, porphyria and active non-infectious disease of the central nervous system
  10. Patients with history of rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
  11. Pregnant or lactating female patients
  12. Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of drug or device within 60 days is anticipated
  13. Unable to participate in the study for any reason in the opinion of the Principal Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Metronidazole

    Immediate release metronidazole

    Drug: Metronidazole

  • Experimental
    Metronidazole-DRF1

    Modified release metronidazole (DRF1)

    Drug: Metronidazole-DRF1

  • Experimental
    Metronidazole-DRF2

    Modified release metronidazole (DRF2)

    Drug: Metronidazole-DRF2

Interventions

  • Immediate release metronidazole 500 mg orally three times a day for 14 days

    Also known as: Flagyl®

  • Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.

    Also known as: Metronidazole

  • Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.

    Also known as: Metronidazole

06

What researchers measure

Primary outcomes

  1. Tolerability

    Tolerability as assessed by physical examination, ECG, clinical laboratory tests and adverse events

    Time frame: 44 Days

  2. Pharmacokinetics

    Systemic pharmacokinetics of metronidazole on Days 1 and 14. Intraluminal colonic concentration of metronidazole as reflected in excreted stool on Days 1 and 14.

    Time frame: 14 Days

Secondary outcomes

  1. Clinical Cure

    Response rate to treatment 2 days after completion of 14 days of metronidazole treatment with no recurrence 30 days after 14 days of metronidazole treatment (Day 44).

    Time frame: 44 Days

  2. Recurrence Rate

    Recurrence defined as re-establishment of diarrhea after clinical cure.

    Time frame: 44 Days

  3. 30-Day Cure Rate

    Clinical cure with no recurrence and no retreatment for 30 days after 14 days of metronidazole treatment (Day 44).

    Time frame: 44 Days

07

Study locations

12 sites
  • Dr. B.R. Ambedkar Medical College
    Bangalore, Karnataka, India
  • St. John's Medical College and Hospital
    Bangalore, Karnataka, India
  • PRS Hospitals
    Trivandrum, Kerala, India
  • B.Y.L. Nair Hospital
    Mumbai, Maharashtra, India
  • Chopda Research and Medical Center Pvt
    Nashik, Maharashtra, India
  • Ruby Hall Clinic
    Pune, Maharashtra, India
  • Deenanath Mangeshkar Hospital
    Pune, Maharastra, India
  • S.P. Medical College and Hospital
    Bikaner, Rajasthan, India
  • Apex Medicical College
    Jaipur, Rajasthan, India
  • Meenakshi Mission Hospital and Research Center
    Madurai, Tamil Nadu, India
  • SKS Hospital India Pvt. Ltd.
    Salem, Tamil Nadu, India
  • Heritage Hospital
    Lanka, Varanasi, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Feb 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2012
First posted
Mar 21, 2012
Start
Mar 2012
Primary completionActual
Feb 2013
CompletionActual
Mar 2013
Last update
Jun 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01559545
Collaborators
Reliance Clinical Research Services (Navi Mumbai, India)
Responsible party
Sponsor
First posted
Mar 21, 2012
Start date
Mar 2012
Primary completion
Feb 2013
Completion
Mar 2013
Last update
Jun 7, 2013

Study contacts

Dilip Pawar, MD
study director · Dr. Reddy's Laboratories Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion